Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch
<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Reason for Revisions</th>
<th>Completed By</th>
</tr>
</thead>
</table>
| 1.0     | Policies and procedures as of October 1, 2015  
Published: February 25, 2016 | New document | FSSA and HPE |
| 1.1     | Policies and procedures as of April 1, 2016  
Published: October 13, 2016 | Semiannual update:  
- Edited and reorganized text throughout for clarity, and removed redundant information  
- Included CHIP-eligible members in introductory paragraph of Program Overview section  
- Updated Table 2 – Billing for EPSDT Visit Concurrent with Sick Visit  
- Replaced Developmental Milestones – Language Skills table with link to the CDC Developmental Milestones page in the Children Younger Than 5 Years Old section  
- Updated description for CPT code 96110 in the Structured Developmental Screening section  
- Added citation for source of Table 4 – Chronology of Visual Development  
- Updated information in the Blood Lead Screening section, including:  
  - Changed Indiana Lead Poisoning Prevention Program to Indiana Lead and Healthy Homes Program  
  - Revised age and test-result level information  
  - Updated procedures and code descriptions in the Procedures for Sending Blood Samples for Lead Testing section  
  - Replaced the Blood Lead Concentration table with three new tables in the | FSSA and HPE |
<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Reason for Revisions</th>
<th>Completed By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2</td>
<td></td>
<td><strong>Interpretation of Blood Lead Test Results and Follow-Up Activities</strong> section</td>
<td>FSSA and HPE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Corrected ICD-9 tuberculosis code in the <em>Tuberculin Test</em> section</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Policies and procedures as of April 1, 2016</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>(CoreMMIS updates as of February 13, 2017)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Published: February 13, 2017</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Replaced reference to Web interChange with Provider Healthcare Portal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Removed ICD-9 references</td>
<td></td>
</tr>
</tbody>
</table>
## Table of Contents

### Section 1: Program Overview
- EPSDT Eligibility ................................................................. 1
  - Managed Care Members .................................................. 1
  - Fee-for-Service Members ................................................. 2
- Required Components of EPSDT/HealthWatch .................. 2
- Diagnostic and Follow-Up Services .................................. 3
- Periodicity and Screening Schedules ................................. 4

### Section 2: Billing and Reimbursement for EPSDT/HealthWatch Services
- EPSDT/HealthWatch Billing Procedures .......................... 7
  - Billing for an EPSDT Visit and Sick Visit (Within the Same Appointment) ........... 8
  - Missed Appointment Procedures ..................................... 9
- Reimbursement for EPSDT/HealthWatch Services .......... 9
  - Third-Party Liability ....................................................... 9
  - Prior Authorization ....................................................... 9

### Section 3: History, Measurements, and Physical Examination
- Family and Medical History ............................................. 11
- Measurements .................................................................. 12
  - Height, Weight, and Head Circumference ..................... 12
  - Blood Pressure ......................................................... 13
- Physical Examination ..................................................... 13

### Section 4: Developmental and Behavioral Assessment
- Development Surveillance .............................................. 15
  - Children Younger Than 5 Years Old .............................. 15
  - Adolescent Maturation .................................................. 16
- Structured Developmental Screening .............................. 16
  - Psychosocial/Behavioral Assessment ......................... 17
  - Substance Abuse Assessment ..................................... 17

### Section 5: Sensory Screenings
- Vision Observation and Screening ................................. 19
  - External Eye Examination .......................................... 19
  - Routine Testing for Visual Acuity ................................. 19
  - Vision Referral Standards ........................................... 21
  - Vision Screening ........................................................ 21
- Hearing Observation and Screening ............................. 22
  - Newborn Hearing Screening ....................................... 22
  - Infant Hearing Screening ............................................. 22
  - Hearing Screening of Older Children ......................... 23
  - Referral Standards ...................................................... 24
  - Audiological High Risk Register ................................. 24

### Section 6: Procedures, Lab Tests, and Immunizations
- Newborn Screening ....................................................... 27
- Immunizations ............................................................... 29
- Blood Lead Screening ..................................................... 29
  - Procedures for Sending Blood Samples for Lead Testing ...... 30
  - Interpretation of Blood Lead Test Results and Follow-Up Activities ...................... 31
  - Hematocrit or Hemoglobin Testing for Iron Deficiency Anemia ....................... 32
- Urinalysis ........................................................................ 32
  - Urinary Albumin and Sugar Testing and Referral Standards .................. 32
  - Bacteriuria Testing and Referral Standards .......................... 33
<table>
<thead>
<tr>
<th>Section</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tuberculin Test</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Sickle Cell Anemia Testing</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>STD and STI Screening</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>HIV Testing</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td><strong>Section 7: Dental Observation and Screening</strong></td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Dental Health Education for Parents</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Education Regarding Lead Poisoning for Pregnant Women and Children 6 Years Old or Younger</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Referrals to Other Healthcare Programs</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Children’s Special Health Care Services</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Indiana’s First Steps Program</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td><strong>Section 8: Health Education and Anticipatory Guidance</strong></td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Dental Health Education for Parents</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Education Regarding Lead Poisoning for Pregnant Women and Children 6 Years Old or Younger</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Referrals to Other Healthcare Programs</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Children’s Special Health Care Services</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Indiana’s First Steps Program</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td><strong>Section 9: Documentation Resources</strong></td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>American Academy of Pediatrics</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Bright Futures</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Centers for Disease Control and Prevention, National Center for Health Statistics</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Indiana State Department of Health</td>
<td>44</td>
</tr>
</tbody>
</table>
Section 1: Program Overview

The federally mandated Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) program, referred to as EPSDT/HealthWatch in Indiana, is a preventive healthcare program designed to improve the overall health of Medicaid and CHIP eligible individuals from birth through the month of their 21st birthday. Special emphasis is given to early detection and treatment of health issues, as these efforts can reduce the risk of more costly treatment or hospitalizations that can result when detection is delayed.

The EPSDT program consists of two mutually supportive, operational components:

- Ensuring the availability and accessibility of required healthcare resources
- Helping Medicaid members and their parents or guardians effectively use these resources

The Indiana Family and Social Services Administration (FSSA) is collaborating with the Indiana Chapter of the American Academy of Pediatrics (INAAP) to develop policies and programs aimed at improving the quality of children’s healthcare and children’s health outcomes. The FSSA has elected to make Bright Futures the standard for infant, child, and adolescent health supervision.

EPSDT/HealthWatch is a required component of Indiana Health Coverage Programs (IHCP) managed care and fee-for-service programs for members who fall within the age range for EPSDT. Specific rules about EPSDT/HealthWatch services can be found in Indiana Administrative Code 405 IAC 5-15.

EPSDT Eligibility

EPSDT/HealthWatch services are available to IHCP members from birth through the month of the member’s 21st birthday. Members eligible for EPSDT services may be enrolled in Healthy Indiana Plan (HIP), Hoosier Care Connect, Hoosier Healthwise, or Traditional Medicaid. It is important to understand the program in which the member is enrolled and follow that program’s procedures for billing.

The State ensures that required services will be provided to qualified individuals recognized as part of a Tribal Nation. The methods and standards for payment are consistent with the current program – not less than one of the following:

- The federal Medicare reimbursement rate for the services provided
- A rate of 130% of the Medicaid reimbursement rate for a service that does not have a Medicare reimbursement rate

Providers may choose to offer EPSDT screenings to only those IHCP patients assigned to their practice or currently being seen in their office. There is no requirement that an IHCP provider accept new patients.

Managed Care Members

Members enrolled in HIP, Hoosier Care Connect, or Hoosier Healthwise have a designated health plan and primary medical provider (PMP). The PMP is expected to personally provide or authorize most primary and preventive care services, including EPSDT services.
The FSSA has contracted with the following managed care entities (MCEs) to manage the care of eligible members and ultimately improve their quality of care and health outcomes:

- Anthem: anthem.com
- Managed Health Services (MHS): mhsindiana.com
- MDwise: mdwise.org

Providers rendering services to members enrolled in a managed care program must refer to the member’s MCE for any additional policies specific to that network. For a complete list of contact information, see the IHCP Quick Reference Guide available at indianamedicaid.com.

Additional information about IHCP managed care programs can be found in the Member Eligibility and Benefit Coverage module and on the Managed Care page at indianamedicaid.com.

Fee-for-Service Members

IHCP members not enrolled in HIP, Hoosier Care Connect, or Hoosier Healthwise are covered under fee-for-service (FFS) Medicaid.

Any provider enrolled in the IHCP, licensed to perform an unclothed physical exam, and providing the components listed in the Required Components of EPSDT/HealthWatch section of this module, is eligible to offer EPSDT/HealthWatch screenings for infants, children, and adolescents.

Required Components of EPSDT/HealthWatch

Ensuring that all children in the IHCP receive age-appropriate, comprehensive preventive services is the primary goal of the EPSDT/HealthWatch program. Components of the screenings and the recommended frequency of the screenings are listed in the EPSDT/HealthWatch Periodicity and Screening Schedule (Figure 1).

EPSDT is a mandatory set of services and benefits for all individuals under age 21 who are eligible for Medicaid. Physicians are accountable for making these services available to all Medicaid-eligible patients; however, members may choose not to participate.

Note: According to 405 IAC 5-15-2, a screening, or any portion of a screening, is not required when medical contraindications are documented.

To provide quality assurance for members who participate in the EPSDT/HealthWatch program, and to claim a higher level of reimbursement for EPSDT services, the following components must be provided and documented:

- Comprehensive health and developmental history, including assessment of physical and mental health development
- Physical examination

A comprehensive unclothed physical exam is required at each EPSDT visit. Guidelines for evaluating the general physical and mental health status for infants, children, and youth to the age of 21 years are described in Bright Futures Guidelines for Health Supervision of Infants, Children, and Adolescents at brightfutures.aap.org.
• Nutritional assessment

A nutritional assessment is required at each EPSDT visit. Assessment is based on the child’s health history, physical exam including oral dental exam, growth pattern, and appropriate blood work. It is also recommended that providers plot body mass index (BMI) beginning at age 2.

• Developmental/behavioral assessment

A developmental assessment is required at each EPDST visit. The detection of developmental delays is an integral component of well-child care.

– Developmental surveillance (the process of recognizing children who may be at risk of developmental delays) should be incorporated into every EPSDT visit.

– Structured developmental screening (the use of standardized tools to identify and refine the risk of developmental delays) should be administered regularly during the 9-month, 18-month, and 30-month visits.

• Vision screening

Vision screening is required at each EPSDT visit. (The objective screening is not separately billable.) Direct referral to an optometrist or ophthalmologist is required when objective screening methods indicate a referral is warranted.

• Hearing screening

Hearing screening is required at each EPSDT visit. Objective testing with audiometer at 4 years old should be administered in the PMP’s office (the simple hearing observation screening is not separately billable), or the patient should be referred to a hearing specialist.

• Dental observation

Dental observation is required at each EPSDT visit. Preventive dental services are recommended every six months or as medically indicated. PMPs are to perform oral dental observations and examinations as part of the EPSDT visit to identify children who require further evaluation and treatment.

• Administration of or referral to any laboratory tests, procedures, or immunizations appropriate for age and risk factors at corresponding EPSDT visit

• Health education

Patient health education is a required component of EPSDT services, and should include documented and appropriate anticipatory guidance. Education and guidance should be conveyed to parents or guardians and children, and designed to assist in understanding what to expect in terms of the child’s development, healthy lifestyle choices, and accident and disease prevention. At the outset, the physical and dental screenings provide the initial context for providing health education.

Diagnostic and Follow-Up Services

Providers must assist in setting appointments on behalf of EPSDT/HealthWatch participants who need diagnostic services or follow-up treatment when indicated as a result of a screening. These additional services may require PMP authorization when performed by a provider other than the PMP.

If assistance is needed to locate a specialist enrolled in the IHCP for referral purposes, contact the Indiana Family Helpline at the Indiana State Department of Health (ISDH) at 1-800-433-0746.
Periodicity and Screening Schedules

Every child and family is unique; therefore, the following periodicity and screening schedule (Figure 1) has been designed as a preventive healthcare plan for children with the absence of any significant health problems and who are growing and developing in satisfactory fashion. This schedule can be adjusted to meet the healthcare needs of specific patients.

The periodicity schedule is meant to be a guide for IHCP providers participating in the EPSDT/HealthWatch program. Providers are encouraged to follow recommendations outlined by the American Academy of Pediatrics (AAP). This program emphasizes the importance of early and periodic screening for specific conditions and the need for continued diagnosis and treatment of conditions and symptoms identified by practicing professionals through the use of this schedule.

The periodicity schedule has also been published in 405 IAC 5-15-8.
Every child and family is unique, therefore this Periodicity and Screening Schedule has been designed as a preventive health care plan for children with the absence of any significant health problems who are growing and developing in satisfactory fashion. This schedule may need to be adjusted to meet the healthcare needs of specific patients. The importance of early and periodic screening for specific conditions, as outlined below, and the need for continued diagnosis and treatment of conditions and symptoms identified by practicing professionals through the use of this schedule. This schedule reflects recommendations of the American Academy of Pediatrics along with those of the Hoosier Healthwise Clinical Advisory Committee and is meant to be a guide for Indiana Medicaid Providers participating in the EPSDT/HealthWatch program. This program emphasizes the frequency of skin testing should be according to the degree of risk. Figure 1 – EPSDT/HealthWatch Periodicity and Screening Schedule per the 405 IAC 2-5-15-8

<table>
<thead>
<tr>
<th>AGE1</th>
<th>HISTORY:INITIAL/INTERVAL MEASUREMENTS</th>
<th>SENSORY SCREENING</th>
<th>DEVELOPMENTAL/BEHAVIOR ASSESSMENT</th>
<th>PHYSICAL EXAMINATION</th>
<th>PROCEDURES – GENERAL</th>
<th>IMMUNIZATION2</th>
<th>LEAD SCREENING3</th>
<th>HEMATOCRIT OR HEMOGLOBIN</th>
<th>URINALYSIS</th>
<th>PROCEDURES – PATIENTS AT RISK</th>
<th>TUBERCULIN TEST13</th>
<th>SICKLE CELL TEST14</th>
<th>DRUG/ HIV TESTING15</th>
<th>STD SCREENING16</th>
<th>PELVIC EXAM</th>
<th>ANTICIPATORY GUIDANCE</th>
<th>INJURY PREVENTION</th>
<th>DENTAL REFERRAL18</th>
<th>DENTAL OBSERVATION</th>
<th>NEWBORN INFANT SCREEN20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NEONATE2</td>
<td>2-4d</td>
<td>By 1mo</td>
<td>2mo</td>
<td>4mo</td>
<td>6mo</td>
<td>8mo</td>
<td>12mo</td>
<td>15mo</td>
<td>18mo</td>
<td>24mo</td>
<td>3y</td>
<td>4y</td>
<td>5y</td>
<td>6y</td>
<td>8y</td>
<td>10y</td>
<td>12y</td>
<td>14y</td>
<td>16y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INFANCY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EARLY CHILDHOOD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MIDDLE CHILDHOOD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADOLESCENCE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1Breastfeeding encouraged and supported. For newborns discharged in less than 48 hours after delivery.
2Developmental, psychosocial, and chronic disease issues for children and adolescents may require frequent counseling and treatment visits separate from preventive care visits.
3If a child comes under care for the first time at any point on this schedule, or if any items are not accomplished at the suggested age, the schedule should be brought up to date at the earliest possible time.
4If the patient is uncooperative, rescreen within six months. If objective vision methods indicate, refer to optometrist/ophthalmologist.
5Not to be duplicated if done in school system.
6By history and appropriate physical examination: if suspicious, by specific objective developmental testing.
7By history and appropriate physical examination:
8Every child and family is unique, therefore this Periodicity and Screening Schedule has been designed as a preventive health care plan for children with the absence of any significant health problems who are growing and developing in satisfactory fashion. This schedule may need to be adjusted to meet the healthcare needs of specific patients.
9To be performed, R = to be performed on patients at risk, S = subjective, by history, O = objective, by standard testing method, = range during which a service may be provided, with the dot or number indicating the preferred age.
10Should be performed one time only, when critically indicated, or if not done in the newborn screen.
11Should be performed on newborns and annually for those at risk, with patient/parent consent.
12All sexually active patients should be screened for sexually transmitted diseases (STDs).
13All sexually active females should have a pelvic examination. A pelvic exam and routine papanicolaou smear should be offered between the ages of 18 and 21 as part of an active preventive health plan.
14Dental referral may include fluoride treatments.
15Should be brought up to date at the earliest possible time.
16Or if any items are not accomplished at the suggested age, the schedule should be brought up to date at the earliest possible time.
17According to the schedule currently recommended by the AAP. Every visit should be an opportunity to update and complete a child’s immunizations.
18A dipstick urinalysis for leukocytes for male and female adolescents.
19Only children deemed to have increased risk of exposure to persons with tuberculosis should be considered for tuberculin (Mantoux) skin testing. The frequency of skin testing should be according to the degree of risk.
20Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch #ICP Provider Reference Module for immunization schedules and risk factor definitions.

Library Reference Number: PROMOD000030
Published: February 13, 2017
Policies and procedures as of April 1, 2016
(CoreMMIS updates as of February 13, 2017)
Version: 1.2
Providers must furnish all components of the Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch examination in accordance with the EPSDT/HealthWatch Periodicity and Screening Schedule (Figure 1), document services performed or referred, and include all applicable diagnosis codes (up to four) for each EPSDT screening exam on the appropriate medical claim form or electronic transaction.

To ensure adherence to EPSDT requirements, the Indiana Health Coverage Programs (IHCP) monitors the following:

- Timely screening as recommended by the EPSDT/HealthWatch Periodicity and Screening Schedule
  - Timely administration of immunizations
  - Hematocrit/hemoglobin testing
  - Blood lead testing
  - Urinalysis
  - Audiometric testing
- Follow-up treatment for diagnosed conditions

### EPSDT/HealthWatch Billing Procedures

EPSDT/HealthWatch claims are billed on the CMS-1500 professional claim form, if submitted on paper, or the Provider Healthcare Portal (Portal) professional claim type or 837P transaction if submitted electronically. Indiana does not require providers to bill EPSDT screenings on a separate EPSDT medical claim form. See the Claim Submission and Processing module, the Provider Healthcare Portal module, and the 837P Health Care Claim: Professional Transaction on the IHCP Companion Guides page at indianamedicaid.com for complete directions for fee-for-service claim submission. For managed care claims, follow the claim submission procedures for the member’s assigned managed care entity (MCE).

The following billing procedures must be followed for every EPSDT/HealthWatch claim, to permit correct and prompt reimbursement:

- For EPSDT claims for dates of service on or after October 1, 2015, providers must use the ICD-10 diagnosis codes **Z00.121** – Encounter for routine child health examination with abnormal findings or **Z00.129** – Encounter for routine child health examination without abnormal findings as the primary diagnosis. (For dates of service before October 1, 2015, use the equivalent ICD-9 code **V20.2** – Routine infant or child health check as the primary diagnosis code.)

  The appropriate preventive health diagnosis code must be used as the primary diagnosis (the first diagnosis code entered in the diagnosis code field). Any other applicable diagnosis codes must be entered in the other positions in the diagnosis code field and cross-referenced accordingly in the diagnosis pointer field for each service detail.

- The appropriate Current Procedural Terminology (CPT®\(^1\)) code for initial or established patient exams (see Table 1) must be included on the first detail line of the claim. For the procedure code billed, the primary diagnosis code – Z00.121 or Z00.129 – must be indicated, with the diagnosis pointer of 1.

- When patient exams are billed in conjunction with Z00.121 or Z00.129 as the primary diagnosis code, the screening components must have been provided.

---

\(^1\) CPT copyright 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
• Physicians are strongly encouraged to include all applicable diagnosis codes (up to eight) and procedure codes on the claim for each EPSDT/HealthWatch visit.

Table 1 – CPT Codes for EPSDT Visits

<table>
<thead>
<tr>
<th>Age</th>
<th>Initial Patient Exam</th>
<th>Established Patient Exam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 1 year</td>
<td>99381</td>
<td>99391</td>
</tr>
<tr>
<td>1–4 years</td>
<td>99382</td>
<td>99392</td>
</tr>
<tr>
<td>5–11 years</td>
<td>99383</td>
<td>99393</td>
</tr>
<tr>
<td>12–17 years</td>
<td>99384</td>
<td>99394</td>
</tr>
<tr>
<td>18–20 years</td>
<td>99385</td>
<td>99395</td>
</tr>
</tbody>
</table>

Claims submitted using any patient exam procedure codes listed in Table 1 are billed in conjunction with Z00.121 or Z00.129 as the primary diagnosis code to identify that all EPSDT screening components have been provided. For services that do not qualify as full screening examinations, use the appropriate office visit codes for the services rendered. Appropriate documentation of the services provided or referred must be included in the patient’s medical records.

Billing for an EPSDT Visit and Sick Visit (Within the Same Appointment)

When a member presents to a provider for a sick visit, and his or her records indicate the need for an updated EPSDT visit, physicians can include services for both visits and bill two visit codes for reimbursement of both services on the same day. Providers must maintain a complete problem-focused visit exam for the presenting problem and a complete preventive visit documenting the EPSDT components of the screening exam within the member’s health records.

Table 2 – Billing for EPSDT Visit Concurrent with Sick Visit

<table>
<thead>
<tr>
<th>Visits</th>
<th>CPT Code</th>
<th>ICD Coding</th>
<th>Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPSDT visit plus sick visit</td>
<td>Preventive visit code</td>
<td>Z00.121 or Z00.129 must be used as the primary diagnosis for the preventive visit, and, for the sick visit, use the appropriate diagnosis codes for the presenting problem.</td>
<td>Additional reimbursement for sick visits depends on complexity and doctor/patient relationship (new/established)</td>
</tr>
<tr>
<td>(two visit codes)</td>
<td>(see Table 1) and 99203–99205 or</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>99213–99215 with modifier 25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If preventive evaluation and management (E/M) procedure codes are used, Z00.121 or Z00.129 should not be used as the primary diagnosis. Providers are allowed to bill an E/M code in conjunction with an EPSDT visit; however, there are specific billing instructions for billing both procedures.

If a patient is evaluated and treated for a problem during the same visit as an EPSDT annual exam, the problem-oriented exam can be billed separately, accompanied by the 25 modifier (separate significantly identifiable E/M service). The problem must require additional moderate-level evaluation to qualify as a separate service on the same date. IHCP reimbursement is allowed at the lesser of the submitted charge or the maximum fee for each code; however, the total billed charge must not be more than the provider charges for similar services provided to private-pay patients.
Missed Appointment Procedures

Claim submission for missed appointments is not required. Any claims submitted for missed appointments are used for data gathering only. There is no reimbursement for missed appointments by any IHCP member, whether that member is enrolled in managed care or not.

Members enrolled under Hoosier Healthwise who miss EPSDT/HealthWatch appointments or follow-up appointments must be identified and their names forwarded to the member’s MCE, the Hoosier Healthwise Helpline, or the Hoosier Healthwise benefit advocate (BA). Providers should refer all HIP and Hoosier Care Connect members with missed appointments to the appropriate MCE for education. For MCE contact information, see the IHCP Quick Reference Guide available at indianamedicaid.com.

Reimbursement for EPSDT/HealthWatch Services

Because EPSDT services include more components than a simple well-child office visit, reimbursement rates for EPSDT/HealthWatch screenings are higher than the rates paid for well-child exams. To offer EPSDT/HealthWatch services, the provider must be licensed to perform an unclothed physical exam, as well as other screening components of the EPSDT examination. IHCP-enrolled providers must adhere to screening and documentation procedures to claim the higher rate of reimbursement for EPSDT/HealthWatch screenings.

Enhanced reimbursement for the initial patient exam is limited to the first EPSDT/HealthWatch screening performed by a screening provider during the participant’s lifetime. If additional claims are received for initial screening from the same provider, reimbursement is allowed at the resource-based relative value scale (RBRVS) rate on file for the billed CPT code, not the higher EPSDT/HealthWatch rate.

Initial and established EPSDT exams are reimbursed when submitted with Z00.121 or Z00.129 as the primary diagnosis, and are subject to the 30-office-visits-per-year limitation without prior authorization. Claims submitted with charges other than the designated amounts for screening exams are paid at the EPSDT/HealthWatch rate or the charged amount, whichever is lower. Examinations that do not contain the screening components or that are not well-child visits by this definition can be billed using the appropriate CPT code for those visits.

To receive appropriate reimbursement, all procedure codes must be accompanied by a diagnosis code. For an EPSDT visit, screening, or immunization, diagnosis code Z00.121 or Z00.129 must be used as the primary diagnosis code.

Third-Party Liability

Federal regulations allow for the bypass of third-party liability (TPL) claim edits when EPSDT/HealthWatch screening procedures are submitted for payment to the IHCP or its MCEs. EPSDT procedure codes are not subject to TPL edits when submitted in conjunction with the primary diagnosis code Z00.121 or Z00.129.

Prior Authorization

Prior authorization (PA) is not required for screening services. EPSDT/HealthWatch exams are subject to the 30-office-visits-per-year limitation without PA. For additional information about services that require PA, consult the IHCP Covered Services and Limitations Rule, 405 IAC 5.

For general information about requesting PA for fee-for-service members, see the Prior Authorization module. For authorization of services provided under a managed care program, consult the member’s MCE for requirements.
Family and Medical History

The history of the patient is an important factor in making a proper assessment of the patient’s health. The Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch screening physician has the responsibility of obtaining a family and medical history as part of the EPSDT screening examination.

This section outlines the categories that should be covered during the history-taking portion of the EPSDT/HealthWatch screening. Modifications should be made that are appropriate for the age and gender of the child. Significant findings should be noted on the child’s medical record.

The following is a suggested outline for the health and development history or database:

- **Reason for visit**
- **Identification of caregivers and initial observations of parent, child, and family interactions**
- **Perinatal history (of child)**
  - *Pregnancy:* Prenatal care (including trimester when initiated); habits, including use of drugs, alcohol, or tobacco; illnesses; accidents; hospitalizations; planned or unplanned
  - *Birth:* Description of labor and delivery; anesthesia; complications; location of birth; full term or premature (gestational age of child)
  - *Neonatal:* Condition at birth; measurements; nursery course; length of stay; complications or problems; treatment; breast or bottle fed
- **Nutritional status**
  - Questions related to feeding or food habits to assess nutritional risk
  - Review the following: height for age and weight for height, laboratory tests, and findings on health history and physical examination
- **Developmental history**
- **Medical history**
- **Body systems review**
- **Family health history**
  Make a notation of the presence of diseases, such as the following, in maternal and paternal families:
  - Allergy
  - Anemia
  - Arthritis
  - Asthma
  - Cancer
  - Congenital anomalies
  - Cystic fibrosis
  - Diabetes mellitus
  - Emphysema
  - Heart disease
  - Hemoglobin disorder
• Hereditary or familial conditions
• Hypertension
• Kidney disease
• Mental illness
• Mental retardation
• Migraine
• Obesity
• Seizures
• Sexually transmitted disease
• Stroke
• Substance use or abuse
• Tuberculosis

• Psychosocial and lifestyle history
• Child’s mental and emotional health
• Family household and environment

Measurements

The following measurements are recommended when performing an EPSDT/HealthWatch exam:

• Height
• Weight
• Body mass index (BMI)
• Head circumference (birth through 2 years)
• Blood pressure (from 3 years)

Height, Weight, and Head Circumference

Guidelines for obtaining measurements:

• **Weight is required at each visit for all ages.** Infants and small children should be weighed on a table-model beam scale. Older children who can stand without support can be weighed on a floor-model beam scale. Scales should be balanced prior to weighing and should be checked and adjusted for accuracy according to the manufacturer’s specifications.

• **Height is required at each visit for all ages.** Infants and children as old as 2 years old and children with low birth weight, failure to thrive, or certain developmental disorders, or who cannot stand, should be measured supine on a firm surface using a fixed headboard and footboard when possible. For older children who are able to stand without support, use a nonstretchable measuring tape fixed to a true vertical surface.

• Head circumference must be measured at every visit for infants and children through 2 years old.
  – Measure the head with a cloth, steel, or disposable paper tape.
  – Apply the tape around the head from the supraorbital ridges anteriorly to the posterior point (usually the external occipital protuberance) giving the maximum circumference.
See the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) percentile standards. If significant deviation is present, conduct further evaluation and, if necessary, make a referral. These growth charts are available from the [CDC NCHS website](https://www.cdc.gov) at cdc.gov.

**Blood Pressure**

Blood pressure must be checked at every screening visit for all children 3 years of age and older. However, blood pressure can be taken on younger children if a provider decides it is appropriate.

- Take the blood pressure with the appropriately sized pediatric or adult cuff.
- Record the reading in the patient chart.

See current percentile charts published by the [American Academy of Pediatrics (AAP)](https://www.aap.org) for the normal blood pressure for various ages. Any significant deviation is a basis for further evaluation and, if necessary, referral.

**Physical Examination**

A complete physical exam must be given each time an EPSDT/HealthWatch screening is performed, with infants totally unclothed and older children undressed and suitably draped. Physicians should always communicate the scope and nature of the physical examination to be performed to the pediatric patient and his or her parent. This communication should address the use of chaperones and issues of patient comfort, confidentiality, and privacy. The use of a chaperone should be a shared decision between the patient and physician.

Physicians evaluate the following items during a complete physical examination:

- Parent, child, and physician interaction
- General appearance and behavior
- Nutrition and growth
- Skin and hair
- Head
- Face
- Eyes
- Ears
- Nose, mouth, and throat
- Teeth and gums
- Musculoskeletal system
- Neck
- Lymph nodes
- Cardiovascular system
- Respiratory system
- Gastrointestinal system
- Urogenital system
  - For adolescents, a pelvic examination may be done when indicated
- Endocrine system
- Nervous system
- Other

Suspect or positive findings should be summarized and discussed with the parent and child, and a plan of care developed.
**Section 4: Developmental and Behavioral Assessment**

Developmental and behavioral assessment is to be completed as part of each Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch visit.

**Developmental Surveillance**

Developmental surveillance is an ongoing process of observations over time, which must be completed as part of each EPSDT/HealthWatch exam. The purpose of developmental surveillance is to consistently observe and determine whether a child’s acquisition of developmental milestones is progressing within a typical developmental range of achievement according to age and cultural background. Parents should be able to give an accurate history of the child’s development; however, a developmental assessment is required. For regular patients, an ongoing recording in the child’s chart of developmental milestones may be sufficient to make a judgment about developmental progress.

**Children Younger Than 5 Years Old**

For children younger than 5 years old, see the Centers for Disease Control and Prevention (CDC) Developmental Milestones page at cdc.gov for milestones for motor language and social development. Every child develops at his or her own, unique rate. These milestones are meant to demonstrate typical developmental stages:

- **Motor skills** – Although practice of motor movements has a slight influence on the rate of development, maturation usually plays a much greater role. The newborn infant can perform a number of motor movements mainly of a reflex type.

  Motor development involving the hands tends to proceed along a definite sequential course. The child first looks from the hand to the object, and then attempts to grasp objects with two hands. Grasping with the palm of the hand is learned first, using the ulnar side of the hand initially, and later the radial side. Eventually, grasping with the thumb and index finger is mastered.

- **Social activity and behavior** – Questions should be asked to determine how the child relates to family and peers and whether there is any noticeable deviation in any behavior. Observe for similar behavior in the office.

- **Speech development** – Attention should be paid to the child’s speech pattern to see whether it is appropriate for the child’s age. Language remains the best predictor of future intellectual endowment and should serve as the common denominator comparing its rate of development with other areas, including gross motor, problem solving, adaptive, and social skills. If a provider decides during the screening process that further evaluation is needed, then one of the standard speech and language tests may be given.

- **Developmental tests** – After observing the child in the various areas of development, the provider may decide that a more in-depth evaluation is needed. The provider can elect to use an objective developmental screening test and receive additional reimbursement. Developmental testing is recommended from 6 months through 4 years old.
If developmental delay is a concern, a referral to First Steps for children birth to 3 years old is recommended. Additional information concerning the First Steps program is located in the Indiana’s First Steps Program section of this document, or use the following information to contact First Steps.

**Bureau of Child Development Services**
402 West Washington Street, Room W386
Indianapolis, IN 46204-2739

**Telephone:** (317) 233-6092  
**Toll-Free Telephone (Indiana residents only):** 1-800-441-STEP (1-800-441-7837)  
**Fax:** (317) 234-6701  
**Email:** FirstStepsWeb@fssa.in.gov

### Adolescent Maturation

Evaluation or referral to an appropriate specialist is indicated if the female patient has not reached the second stage of breast development by 13 years old or menarche by 16 years old.

Evaluation or referral to an appropriate specialist is indicated if the male patient has not reached the second stage of genitalia maturation by 13.5 years old.

### Structured Developmental Screening

EPSDT/HealthWatch providers are allowed to bill for a structured developmental screening in addition to an EPSDT screening at the 9-month, 18-month, and 30-month visit. Providers also have the option of conducting the structured developmental screening anytime that surveillance (medical history of developmental risk factors, parental/caregiver concern) identifies a need. Providers are encouraged to use standardized screening tools that have a moderate to high sensitivity, specificity, and validity level and are culturally sensitive. The following Current Procedural Terminology (CPT) code, which is limited to five units per date of service (five different screening tools used), may be used when billing for standardized screening:

96110 – Developmental screening (e.g., developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument

Examples of screening tools allowed for this code include, but are not limited to:

- Ages and Stages Questionnaire (ASQ)
- Ages and Stages Questionnaire/Social Emotional (ASQ-SE)
- Denver DST/Denver II
- Battelle Developmental Screener
- Bayley Infant Neurodevelopment Screener (BINS)
- Parents Evaluation of Development (PEDS)
- Early Language Accomplishment Profile (ELAP)
- Brigance Screens II
- Modified Checklist for Autism in Toddlers (M-CHAT)
- Vanderbilt Rating Scales
- Behavior Assessment Scale for Children-Second Edition (BASC-II)

EPSDT/HealthWatch providers must document the screening tool utilized, with interpretation and report, in the child’s medical record.
Psychosocial/Behavioral Assessment

The federal EPSDT mandate requires regularly scheduled screenings of all Medicaid-enrolled children to identify physical and mental health problems. To make early identification of behavioral and emotional problems easier and cost-effective for busy physicians, a screening questionnaire can be used as part of routine primary care to facilitate early recognition. Many regularly used tools are available in English and Spanish.

Substance Abuse Assessment

Urine testing to establish drug abuse seems a tempting and objective means of overcoming the problems of denial, unreliable histories, and the less-than-clear-cut signs and symptoms. However, there are problems of sensitivity and specificity in urine screens. False negatives occur because of innocent confounding substances. The physician’s role in substance abuse screening, through obtaining a history of the patient, is identification and referral.
Section 5: Sensory Screenings

Vision and hearing screenings, either subjective (by history) or objective (by standard testing method), are required at each Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch visit.

Vision Observation and Screening

Undetected vision problems occur in 5%–10% of preschool children. The most serious of these problems is amblyopia, a loss of visual acuity and binocular vision that becomes irreversible after 5 years old.

Each EPSDT screening must include a visual observation with an external eye examination and routine testing for visual acuity. This visual observation is a component of an EPSDT screening exam and is not separately billable. See Table 3 for timings of required screenings.

Vision referrals must be made when objective screening methods indicate that a referral is warranted.

Table 3 – IHCP Periodicity Schedule for EPSDT/HealthWatch Vision Observation and Screening

<table>
<thead>
<tr>
<th>Age of Child</th>
<th>Subjective (S) or Objective (O)</th>
<th>Services Required or Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 3 years</td>
<td>S</td>
<td>Visual observation with an external eye examination; subjective screening by history. Refer child to an appropriate specialist if abnormality suspected.</td>
</tr>
<tr>
<td>3 to 5 years</td>
<td>O</td>
<td>Annual objective screening test by a standard testing method. If warranted, refer child to an appropriate specialist.</td>
</tr>
<tr>
<td>6, 8, 14, 16, and 20 years</td>
<td>S</td>
<td>Visual observation with an external eye examination; subjective screening by history. Refer child to an appropriate specialist if abnormality suspected.</td>
</tr>
<tr>
<td>10, 12, and 18 years</td>
<td>O</td>
<td>Objective screening test by a standard testing method. If warranted, refer child to an appropriate specialist.</td>
</tr>
</tbody>
</table>

External Eye Examination

The external eye examination should include general inspection of the lids and eyeballs, noting prominence, size, and position, as well as growths, inflammations, discharge, or vascular injection. Forward protrusion (exophthalmos) or retraction (enophthalmos) of the globe should be noted.

Abnormalities that cannot be adequately evaluated and treated by the screening physician should be referred to a specialist for further evaluation.

Routine Testing for Visual Acuity

Any marked deviation from the guidelines in Table 4 is a basis for referral to a specialist for further evaluation.
Table 4 – Chronology of Visual Development

<table>
<thead>
<tr>
<th>Age</th>
<th>Level of Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>Awareness of light and dark and closes eyelids in bright light.</td>
</tr>
<tr>
<td>Neonatal</td>
<td>Rudimentary fixation on near object (3 to 30 inches).</td>
</tr>
<tr>
<td>2 weeks</td>
<td>Transition fixation, usually monocular, at a distance of roughly three feet.</td>
</tr>
<tr>
<td>4 weeks</td>
<td>Follows large, conspicuously moving objects.</td>
</tr>
<tr>
<td>6 weeks</td>
<td>Moving objects evoke binocular fixation briefly.</td>
</tr>
<tr>
<td>8 weeks</td>
<td>Follows moving objects with jerky eye movements. Convergence beginning to appear.</td>
</tr>
<tr>
<td>12 weeks</td>
<td>Visual following now a combination of head and eye movements and convergence improving. Enjoys light objects and bright colors.</td>
</tr>
<tr>
<td>16 weeks</td>
<td>Inspects own hands. Fixates immediately on a one-inch cube brought within one to two feet of eye. Vision 20/300 to 20/200 (6/100 to 6/70)</td>
</tr>
<tr>
<td>20 weeks</td>
<td>Accommodative convergence reflexes all organizing. Visually peruse lost rattle. Shows interest in stimuli more than three feet away.</td>
</tr>
<tr>
<td>24 weeks</td>
<td>Retrieves a dropped one-inch cube, can maintain voluntary fixation of stationary object even in the presence of competing moving stimulus, and hand-eye coordination appearing.</td>
</tr>
<tr>
<td>26 weeks</td>
<td>Will fixate on a string.</td>
</tr>
<tr>
<td>28 weeks</td>
<td>Binocular fixation clearly established.</td>
</tr>
<tr>
<td>36 weeks</td>
<td>Beginning of depth perception.</td>
</tr>
<tr>
<td>40 weeks</td>
<td>Marked interest in tiny objects and tilts head backward to gaze up. Vision 20/200 (6/70)</td>
</tr>
<tr>
<td>52 weeks</td>
<td>Fusion beginning to appear. Discriminate simple geometric forms (squares and circles). Vision 20/180 (6/60)</td>
</tr>
<tr>
<td>12–18 months</td>
<td>Looks at pictures with interest.</td>
</tr>
<tr>
<td>18 months</td>
<td>Convergence well established and localization of distance is crude - runs into large objects.</td>
</tr>
<tr>
<td>2 years</td>
<td>Accommodation well developed. Vision 20/40 (6/12)</td>
</tr>
<tr>
<td>3 years</td>
<td>Convergence smooth and fusion improving. Vision 20/30 (6/9)</td>
</tr>
<tr>
<td>4 years</td>
<td>Vision 20/20 (6/6)</td>
</tr>
</tbody>
</table>


**Visual Acuity – Infants**

Visual acuity is difficult to evaluate in infants. Providers should observe whether an infant follows a light or a bright attractive toy in different directions of gaze. Each eye should be tested separately. If the infant fails to respond to such testing, the provider should observe the pupillary responses for reaction to direct light stimulus.

Infants can be tested by alternately covering each eye. If visual acuity is poor in one eye, the infant resists actively when the good eye is covered and vision is disturbed, but is much less affected when the eye with decreased vision is covered.
Visual Acuity – Children 36–59 Months

The most direct way to detect amblyopia (monocular decreased vision) in 3- and 4-year-old children is to assess monocular visual acuity. Recommended tests include Lea symbols, or tumbling E charts, because they allow screening of younger children. Isolated optotypes with surround bars are also acceptable. Stereopsis testing is recommended to detect strabismus as an amblyopiogenic factor.

Vision Referral Standards

Referrals to an appropriate eye or vision specialist must be made when objective screening methods indicate that a referral is warranted. A child may also be referred if parental complaints warrant a referral. Children failing a test for hyperopia can be referred for additional diagnosis and treatment.

Screening results from school should be documented in the patient’s record. Vision screens should be completed within the public schools as a requirement of the Indiana Department of Education in the first, third, and eighth grades. Parents may be able to share results, which may include a formal referral for additional testing.

Vision Screening

Table 5 provides testing procedures and passing criteria for one commercially available vision test.

Table 5 – Testing Procedures

<table>
<thead>
<tr>
<th>Function to Be Evaluated</th>
<th>Type of Test</th>
<th>Specific Test</th>
<th>Recommended Testing Procedures</th>
<th>Passing Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stereopsis</td>
<td>Random dot stereogram</td>
<td>Random Dot E</td>
<td>Test distance = 40 cm (630 arcsec)</td>
<td>Child must locate stereo E on four of five presentations.*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>All testing, including pretesting, should be performed binocularly with the polarized glasses.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Pretest – Test child’s ability to perform test by having child identify the location of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>three-dimensional E on four of five trials (E on left or right; above or below).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Test procedure – Test child’s ability to identify the location for the stereo E. Tester should</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>use five presentations, varying location in a nonsystematic manner.</td>
<td></td>
</tr>
</tbody>
</table>

* From a statistical perspective, it would be ideal to require a child pass five of five trials, because the probability of achieving this criterion by simply guessing is less than 5%. In reality, many children will have difficulty attending consistency for five trials. Therefore, four of five correct passing criteria is considered acceptable, even though the probability of passing by chance is 16.5%.
Hearing Observation and Screening

The American Academy of Pediatrics (AAP) supports the goal of universal detection of hearing loss in infants before 3 months of age, with appropriate intervention no later than 6 months of age. Universal detection of hearing loss requires universal screening of all infants. Screening tests that vary according to age must be part of the EPSDT/HealthWatch screening.

Newborns identified under the universal newborn hearing screening (UNHS) program or confirmed to have hearing loss should be referred to First Steps. Children between the ages of newborn through 3 years old may qualify for early intervention services through First Steps. These services provide information about the range of available options so that parents can make the best decision regarding care and treatment of their child. For more information about the Indiana First Steps Program, see the First Steps page on the Family and Social Services Administration (FSSA) website.

Refer children 4 years of age and older for additional testing and treatment to an audiologist when screening results identify a possible hearing deficit.

Newborn Hearing Screening

Newborns that do not pass the newborn hearing screen should have their hearing evaluated by an audiologist as soon as possible. This evaluation is done to determine how a baby is hearing, as well as look for possible causes of hearing loss.

The most critical period for learning language is during the first two years of life. If hearing problems are not detected until after this time, lost ground in language development may never fully be regained. The early detection of hearing loss is an urgent duty of any physician caring for young children.

Diagnostic testing uses the automated auditory brainstem test and other tests to determine how a baby hears. The tests can be done at various loudness levels and at different pitches (high sounds and low sounds). If testing is done before 3 months of age, the tests can usually be completed while the baby sleeps. For older or more active babies, medicine may be needed to help the baby sleep during the tests. It is important for babies to be quiet and not move much during testing, so the results of the diagnostic testing are accurate.

Note: UNHS is designed to identify infants, ensure appropriate follow-up intervention, and collect information on the evidence of hearing loss using the initial guidance package published by the Indiana State Department of Health (ISDH). For further information, contact the ISDH at (317) 234-3358.

Infant Hearing Screening

Noisemakers can be used to screen an infant’s hearing. High frequencies can be tested with a squeaky toy or small bell, and middle frequencies with a rattle or piece of tissue paper. While the infant is distracted with a visual stimulus, such as a toy or brightly colored object, the noisemaker is sounded outside the field of vision. Normal responses are as follows:

- At 4 months, there is a widening of the eyes, a cessation of previous activity, and possibly a slight turning of the head in the direction of the sound.
- At 9 months or older, the child should usually be able to locate sound, whether it comes from above or below.

Many hearing tests, such as banging pots together or hearing a low-flying airplane, can falsely give normal results. Most children with significant hearing deficits have residual hearing and respond to very loud noises. However, they are educationally and socially deaf if they cannot hear normal speech sounds.
**Hearing Screening of Older Children**

At age 3 years, a child can begin to be tested with a pure tone audiometer. However, EPSDT/HealthWatch does not require an audiometric screening until the child reaches 4 years old. If the child is unable to cooperate, the test can be deferred until the next exam. Deferral due to inability to cooperate should be documented in the patient record.

Hearing screening must be done with an audiometer or audioscope. Providers that do not wish to perform the objective hearing screen can refer the child to an audiologist for screening.

Hearing screening should be completed within the public schools as a requirement of the Indiana Department of Education in first, fourth, seventh, and tenth grades. Some schools also test kindergarten children. These screening efforts should not be duplicated unless the child is at risk and the situation warrants rescreening. Screening results from the school should be documented in the patient’s medical records. Parents may be able to share results, which may include a formal referral for additional testing.

See Table 6 for timing of required screenings.

**Table 6 – IHCP Periodicity Schedule for EPSDT/HealthWatch Hearing Observation and Screening**

<table>
<thead>
<tr>
<th>Age of Child</th>
<th>Subjective (S), Objective (O), or Required (R)</th>
<th>Services Required or Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn</td>
<td>R</td>
<td>Newborn hearing screening via fully automated auditory brain stem response, if available.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Note:</strong> All patients considered to be at risk for hearing deficit are to be screened at this time.</td>
</tr>
<tr>
<td>Under 12 months</td>
<td>S</td>
<td>Subjective screening, by history and/or other infant screening techniques; refer child to an appropriate hearing specialist, if warranted.</td>
</tr>
<tr>
<td>12 months through 4 years</td>
<td>O</td>
<td>As early as possible, perform an objective screening using a standard testing method. Refer those at risk or suspected of hearing deficit to a specialist.</td>
</tr>
<tr>
<td>4 to 5 years</td>
<td>R</td>
<td>Audiometric screening with an audiometer or audioscope (child may be referred to an audiologist for screening); refer child at risk or suspected of hearing deficit to an appropriate specialist.</td>
</tr>
<tr>
<td>4, 8, 14, 16, and 20 years</td>
<td>S</td>
<td>Subjective screening by history and/or other method; refer child with suspected hearing deficit to an appropriate specialist.</td>
</tr>
<tr>
<td>10, 12, and 18 years</td>
<td>O</td>
<td>Objective hearing screening by a standard testing method (hearing tests are given by the Indiana Department of Education in grades 1, 4, 7, and 10 – several schools also test kindergarten students). <strong>Do not duplicate school screenings unless the child is considered at risk and rescreening is warranted.</strong></td>
</tr>
</tbody>
</table>

See the [Audiological High Risk Register](#) section for categories of patients often associated with unsuspected hearing loss.
Referral Standards

When a chronic hearing deficit is suspected or has been confirmed, an appropriate referral should be arranged to do precise testing. If the hearing deficit is confirmed, the patient should be referred to an otolaryngologist for examination in an attempt to determine what treatment may be necessary.

Audiological High Risk Register

The following are considered audiological high risk register (HRR):

- **Neonates (birth to 28 days)** who fall into one or more of the 10 risk criteria identified by the Joint Committee on Infant Hearing (1990) are considered at risk for hearing impairment and should receive audiologic screening. The factors frequently referred to as the HRR are:
  - Family history of congenital or delayed onset childhood sensorineural impairment
  - Congenital infection known or suspected to be associated with sensorineural hearing impairment such as toxoplasmosis, syphilis, rubella, cytomegalovirus, and herpes
  - Craniofacial anomalies, including morphologic abnormalities of the pinna and ear canal, absent philtrum, low hairline, and so forth
  - Birth weight less than 1,500 grams (less than 3.3 pounds)
  - Hyperbilirubinemia at a level exceeding indication for exchange transfusion
  - Otoxic medications, including, but not limited to, the aminoglycosides, used for more than five days (such as, gentamicin, tobramycin, kanamycin, streptomycin) and loop diuretics used in combination with aminoglycosides
  - Bacterial meningitis
  - Severe depression at birth, which may include infants with Appearance, Pulse, Grimace, Activity, Respiration (APGAR) scores of 0–3 by five minutes or those who fail to initiate spontaneous respiration by 10 minutes or those with hypotonia persisting to 2 hours of age
  - Prolonged mechanical ventilation for a duration equal to or greater than 10 days, such as persistent pulmonary hypertension
  - Stigmata or other findings associated with a syndrome to include sensorineural hearing loss, such as Wardenburg or Usher’s Syndrome

- **Infants (29 days to 2 years)**
  - Parent or caregiver concerns about hearing, speech, or developmental delay
  - Bacterial meningitis
  - Neonatal risk factors that may be associated with progressive sensorineural hearing loss, such as cytomegalovirus, prolonged mechanical ventilation, and inherited disorders
  - Head trauma, especially with either longitudinal or transverse fracture of the temporal bone
  - Stigmata or other findings associated with syndromes known to include sensorineural hearing loss, such as Wardenburg or Usher’s Syndrome
  - Otoxic medications including, but not limited to, the aminoglycosides used for more than five days, such as gentamicin, tobramycin, kanamycin, streptomycin, and loop diuretics used in combination with aminoglycosides
  - Neurodegenerative disorders such as neurofibromatosis, myoclonic epilepsy, Friedreich’s Ataxia, Huntington’s Chorea, Werdnig-Hoffman Disease, Tay-Sach’s Disease, Charcot-Marie Tooth Disease, any metachromatic leukodystrophy, or any infantile demyelinating neuropathy

- **Screening test failures**
  - Infants who fail any of the office screening tests described previously should be given more sensitive tests to clarify hearing status.
• Suggestive symptoms in infants
  – Concerned parents – Most parents of deaf children have some suspicion of the problem by the time the child is 6 months old and sometimes earlier. When the parent suspects hearing impairment, a reliable hearing test should be given.
  – Not awakening to sound – A normal sleeping infant sometimes awakens to sounds in other parts of the house. If this behavior has not been observed, the parent should be asked to be alert for it and to report observations at the next EPSDT/HealthWatch visit. If it does not occur, the child requires referral.

• Speech delays
  – Before any child is labeled as having intellectual disability, autism, auditory agnosia, or a developmental speech delay, a valid hearing test is required. Verbal communication depends on hearing. If the patient is old enough to cooperate with pure tone audiometry and the results are normal, referral to an audiologist is not needed. Referral to an audiologist should be preceded by otoscopic examination.
Section 6: Procedures, Lab Tests, and Immunizations

Providers must provide or arrange for all the appropriate Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch services for each child at each age level in a timely manner, and properly document and bill the services. The Indiana Health Coverage Programs (IHCP) and managed care entities (MCEs) closely monitor all claims submitted to ensure that appropriate procedures are provided and to give the provider feedback concerning age-specific EPSDT/HealthWatch service delivery. See the EPSDT/HealthWatch Periodicity and Screening Schedule (Figure 1).

Newborn Screening

Newborn screening results must be recorded in the patient record for infants younger than 1 year old. Newborn screenings are tests to be given at the earliest feasible time for the detection of the following disorders:

- Galactosemia
- Hemoglobinopathies, including sickle cell anemia
- Homocystinuria
- Hypothyroidism
- Maple syrup urine disease
- Phenylketonuria (PKU)
- Congenital adrenal hyperplasia
- Biotinidase deficiency
- Medium Chain Acyl-Coenzyme A Dehydrogenase (MCAD) deficiency
- 34 other amino acid defects, fatty acid oxidation defects, and/or organic acidemias
- Cystic fibrosis (CF)
- Critical congenital heart disease (CCHD)
  - Testing for CCHD should be performed after 24 hours of birth and before discharge from hospital, in accordance with American Academy of Pediatrics (AAP) guidelines.
- Medium chain acyl-coenzyme A dehydrogenase (MCAD) deficiency
- Other genetic conditions that are detectable at birth via newborn screening methods, including, but not limited to, the following:
  - Tandem mass spectrometry (MS/MS)
  - High volume radioimmunoassay
  - Hemoglobin electrophoresis
  - Isoelectric focusing
  - Bacterial inhibition assays
  - Immunoreactive trypsinogen (IRT)
  - DNA testing
All blood samples are collected by the hospital on a filter paper card that must also contain information to identify the infant, the infant’s physician as provided by the mother, the time of birth, the time of the first feeding, and time of the blood draw. The blood sample is sent to the Indiana University (IU) Laboratory. IU is contracted by the Indiana State Department of Health (ISDH) to perform the laboratory analysis for newborn screening. There is a charge from the IU Laboratory to the hospital for the initial test, but if a retest is needed, there is no additional charge by the IU Laboratory. If the IU Laboratory requests further testing in the form of serum or whole blood collection, that testing is provided at no charge. The IU Laboratory indicates in the letter to the physician whether additional testing of serum or whole blood is indicated.

Note: IHCP providers using laboratories other than the IU Laboratory to perform newborn screening analysis should discontinue this practice immediately.

Use of laboratories other than IU increases newborn screening costs unnecessarily. To ensure that the IU Laboratory performs all newborn screening, all newborn screening should be coordinated through the ISDH. Providers must determine whether valid newborn screening test results have been obtained for the infant. If a valid test has been obtained for the infant and the test results were normal, no further testing is required. The newborn screening process is complete.

If a rescreening is needed because the first screening was invalid, additional testing of serums is needed because test results were abnormal, or there is no record that newborn screening was done, providers should call ISDH to work out the best method of accomplishing newborn screening. Generally, the ISDH recommends that the infant be taken back to the birth hospital to have that hospital perform newborn screening or rescreening; however, providers should consult with the ISDH on how best to proceed with newborn screening when there is an invalid or abnormal test. If additional information is needed, contact the following:

Newborn Screening Program
Indiana State Department of Health
2 North Meridian Street, Suite 700
Indianapolis, IN 46204
Telephone: (317) 233-1270 or 1-888-815-0006
Fax: (317) 234-2995

Because newborns can be released from hospitals prior to the 48 hours needed to obtain valid newborn screening results, an increasing number of newborns require a second screening. Families are generally asked to bring the newborn back to the birth hospital as an outpatient, or the hospital requests that a nurse make a follow-up visit to obtain the sample for newborn screening. In either case, the hospital could potentially bill the IHCP separately for newborn screening, which is already included in the diagnosis-related group (DRG) that the IHCP pays for the newborn hospitalization.

Hospitals are not permitted to bill the IHCP separately for newborn screenings. There are occasions when hospitals are requested to perform newborn screening for newborns born in another Indiana hospital. For example, when distance precludes a trip to the birth hospital, the infant should be taken to the nearest hospital with birthing facilities so that newborn screening can be completed. To prevent the second hospital from being charged by the IU Laboratory for the second screen, the hospital must indicate on the filter paper card, in the space provided, the name of the birth hospital and the submitting hospital. The IU Laboratory attempts to match the infant’s second screen with the first screen so that the hospital is not charged. If the infant's name or birth date has been changed, the original name and date of birth must be included in the information sent to the IU Laboratory to facilitate a match.
Immunizations

Immunizations should be provided or arranged for each child according to the schedule recommended by the AAP. Every EPSDT/HealthWatch visit should be an opportunity to update and complete a child’s immunizations.

The federal Vaccines for Children (VFC) program makes available, at no cost to providers, certain vaccines for administration to IHCP members 18 years old and younger. If an EPSDT/HealthWatch provider chooses not to participate in the VFC program, the provider must document the IHCP-enrolled patient’s immunization history.

For more information about the VFC program, see the Injections, Vaccines, and Other Physician-Administered Drugs module. For a list of VFC-available vaccines, see the Injections, Vaccines, and Other Physician-Administered Drugs Codes on the Code Sets page at indianamedicaid.com.

Blood Lead Screening

The ISDH, through the Indiana Lead and Healthy Homes Program (ILHPP), monitors lead poisoning in Indiana children. Children from 6 months through 6 years of age are at greatest risk for elevated blood lead levels.

ICLPPP has identified the following four steps to a successful lead poisoning prevention program:

1. Early identification of children with excessive lead absorption through screening programs
2. Treatment of children with abnormal blood lead levels
3. Prompt termination of further excessive lead exposure (environmental investigation and abatement)
4. Intensive parent and public education about lead poisoning (see Education Regarding Lead Poisoning for Pregnant Women and Children 6 Years Old or Younger)

Screening for blood lead toxicity for all children enrolled in Medicaid is a federal requirement. The Family and Social Services Administration (FSSA) requires that all children enrolled under Medicaid receive a blood lead screening test at 12 months and 24 months of age. If the member is at high risk for lead exposure at the 6-month visit or the 9-month visit, a screening should be performed earlier. Children between the ages of 36 months and 72 months of age must receive a blood lead screening if they have not been previously tested for lead poisoning. A blood lead test result equal to or greater than 5 ug/dl obtained by capillary specimen (fingerstick) must be confirmed using a venous blood sample. Subsequent screenings are required for at-risk patients.

When a subsequent blood lead screening is performed, use the ICD-10 diagnosis code Z77.011 – Contact with and (suspected) exposure to lead in addition to the primary diagnosis code of Z00.121 or Z00.129.

Note: The lead exposure diagnosis code (Z77.011) should only be used when children are diagnosed as lead exposed.

The following items place a child at risk for lead poisoning:

- Children with high incidence of hand-to-mouth activity, such as thumb sucking or nail biting
- Children with a history of pica (a medical disorder characterized by a craving for nonfood items, such as peeling paint, dirt, and cigarette butts)
- Children living in housing constructed prior to 1978, who may be exposed to lead pipes or lead-based paints
• Children living in or frequently visiting poorly maintained housing units constructed prior to the 1960s or who are exposed to other hazardous lead sources (such as children of lead industrial workers)
• Children living in older homes that are being restored
• Children with poor nutritional status (increased fat, decreased calcium, iron, and other nutrients), predisposing them to enhanced lead absorption in the intestines
• Children with a previously elevated blood lead level
• Children with signs and symptoms of lead poisoning
• Painted household surfaces such as cribs, window sills, toys, doors, radiators, or fallen paint chips, flaking areas, and holes in the walls
• Lead water pipes
• Soil, dirt, and dust inside and outside a dwelling
• Imported brands of plastic mini-blinds
• Paper, newsprint, magazine pages, and metallic wrapping paper
• Playground equipment with chipped lead-based paint
• Water wells
• Industrial crayons, batteries, rubber, electronic devices, printed material (yellow and orange inks or oil colors may contain lead chromate), cans, varnishes, shellac, and paints on containers
• Unglazed food containers or pottery that have been lead glazed, lead alloyed, plated, or soldered
• Fungicides, insecticides, cosmetics, and various medications, which can contain lead carbonate
• Cigarette butts, decorative candle wicks, and matches, which can contain lead acetate
• Burning painted lumber and battery casings, which can place lead in the air
• Folk remedies, such as greta and azarcon used to treat diarrhea or gastrointestinal upset, which can contain substantial amounts of lead

**Procedures for Sending Blood Samples for Lead Testing**

The FSSA recommends that blood samples drawn for lead screening be sent to the ISDH Laboratories to ensure that testing is done on atomic absorption spectrophotometers (AAS) and to ensure that the results are known to the ILHPP. Blood samples should be sent to:

**ISDH Laboratories**
**Blood Lead Lab**
550 West 16th Street, Suite B
Indianapolis, IN 46202

Providers that use the ICLPPP’s postage-paid kit cannot bill the IHCP a conveyance fee for conveying samples to the lab. However, providers can still use code 36415 – *Collection of venous blood by venipuncture*, to indicate that blood draws were made. The distinction must be made by diagnosis to differentiate between individuals being tested to rule out lead screening and those that have been diagnosed or are being treated for lead poisoning.

When forwarding blood samples to ISDH/ICLPPP, primary medical providers (PMPs) must include their provider number and authorization code for members on the paperwork accompanying the sample. If the member is enrolled in a managed care program, include the MCE PMP authorization and referral information.
Providers that send blood samples to private labs for testing should use the codes in Table 7, when appropriate.

Table 7 – Provider Billing for Blood Samples Sent to Private Labs

<table>
<thead>
<tr>
<th>Code</th>
<th>Code Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>36415</td>
<td>Collection of venous blood by venipuncture</td>
</tr>
<tr>
<td>99000*</td>
<td>Handling and/or conveyance of specimen for transfer from the office to a laboratory</td>
</tr>
<tr>
<td>99001*</td>
<td>Handling and/or conveyance of specimen for transfer from the patient in other than office to a laboratory (Distance may be indicated)</td>
</tr>
</tbody>
</table>

*Can only be submitted if the provider incurs an expense associated with the conveyance*

The coverage and reimbursement rate for code 83655 – *Lead, quantitative, blood* is expanded to include tests administered using filter paper (U1 modifier) and handheld testing devices (U2 modifier) in the office setting, as indicated in Table 8.

Table 8 – Codes for Lead Testing

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>83655 U1</td>
<td>Lead, quantitative, blood, using filter paper</td>
</tr>
<tr>
<td>83655 U2</td>
<td>Lead, quantitative, blood, using handheld testing device</td>
</tr>
<tr>
<td>83655</td>
<td>Lead, quantitative, blood</td>
</tr>
</tbody>
</table>

**Interpretation of Blood Lead Test Results and Follow-Up Activities**

Interpretation of blood lead test results and follow-up activities are grouped into different classes. See Tables 9, 10, and 11 and cdc.gov for CDC recommended guidance on actions, receiving confirmatory samples, and follow-up testing.

Table 9 – Recommended Actions Based on Blood Lead Level

<table>
<thead>
<tr>
<th>Class</th>
<th>Blood Lead Concentration (µg/dl)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt; 5</td>
<td>A child in Class I is not considered to be lead-poisoned.</td>
</tr>
<tr>
<td>II</td>
<td>5–44</td>
<td>A child in Class II may need to be rescreened more frequently. A child in Class II should receive nutritional and educational intervention and be rescreened within one month. A child in Class II should receive environmental evaluation, remedication, and a medical evaluation and neurodevelopmental monitoring. If the blood lead level persists in this range, environmental investigation and intervention should be done. A child in this class may need pharmacologic treatment of lead poisoning. Rescreen the child within one week to one month with higher level being more urgent need for confirmatory testing.</td>
</tr>
<tr>
<td>III</td>
<td>45–69</td>
<td>A child in Class IV will need both medical and environmental interventions, including chelation therapy within 48 hours.</td>
</tr>
<tr>
<td>IV</td>
<td>≥ 70</td>
<td>A child with Class V lead poisoning is a <strong>medical emergency</strong>. Medical and environmental management must begin immediately.</td>
</tr>
</tbody>
</table>
Table 10 – Recommended Schedule for Obtaining a Confirmatory Venous Sample

<table>
<thead>
<tr>
<th>Blood µg/dl</th>
<th>Time to Confirmation Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 5–9</td>
<td>1–3 months</td>
</tr>
<tr>
<td>10–44</td>
<td>1 week – 1 month *</td>
</tr>
<tr>
<td>45–59</td>
<td>48 hours</td>
</tr>
<tr>
<td>60–69</td>
<td>24 hours</td>
</tr>
<tr>
<td>≥ 70</td>
<td>Urgently as emergency test</td>
</tr>
</tbody>
</table>

* The higher the blood lead level on the screening test, the more urgent the need for confirmatory testing.

Note: Adapted from: Screening Young Children for Lead Poisoning: Guidance for State and Local Public Health Officials. Atlanta: 5 CDC; 1997.

Table 11 – Schedule for Follow-Up Blood Lead Testing*

<table>
<thead>
<tr>
<th>Venous Blood Lead Level µg/dl</th>
<th>Early Follow-Up Testing (2–4 Tests after Identification)</th>
<th>Later Follow-Up Testing after Blood Lead Level Declining</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥5–9</td>
<td>3 months **</td>
<td>6–9 months</td>
</tr>
<tr>
<td>10–19</td>
<td>1–3 months **</td>
<td>3–6 months</td>
</tr>
<tr>
<td>20–24</td>
<td>1–3 months **</td>
<td>1–3 months</td>
</tr>
<tr>
<td>25–44</td>
<td>2 weeks – 1 month</td>
<td>1 months</td>
</tr>
<tr>
<td>≥45</td>
<td>As soon as possible</td>
<td>As soon as possible</td>
</tr>
</tbody>
</table>

* Seasonal variation of BLLs exists and may be more apparent in colder climate areas. Greater exposure in the summer months may necessitate more frequent follow-ups.

** Some case managers or primary care physicians may choose to repeat blood lead tests on all new patients within a month to ensure that their blood lead level is not rising more quickly than anticipated.

Hematocrit or Hemoglobin Testing for Iron Deficiency Anemia

The purpose of screening for anemia is to uncover correctable nutritional anemia, such as iron deficiency anemia. Providers should follow current clinical standards for diagnosis of anemia based upon age of the child.

Urinalysis

Urinary Albumin and Sugar Testing and Referral Standards

Tests for urinary albumin and sugar must be done on every child – routinely at 5 years old, or at every screening, if clinically indicated or not done previously. Dipsticks are acceptable for testing.

A positive test must be suitably followed up or referred for further care. A 1+ albumin (or trace) with no symptoms need not be referred, as it is not an unusual finding.
**Bacteriuria Testing and Referral Standards**

Screening is recommended if there are symptoms related to possible urinary tract infections.

**Tuberculin Test**

Information published by the AAP indicates that the most reliable tuberculosis control program is based on aggressive, expedient contact investigations, rather than routine skin test screening. The AAP recommends that all routine pediatric healthcare evaluations include assessment of risk of exposure to tuberculosis.

Only children deemed to have increased risk of exposure to persons with tuberculosis should be considered for tuberculin (Mantoux) skin testing. For children who receive a tuberculosis assessment that results in a skin test, use ICD-10 diagnosis code Z20.1 – *Contact with and (suspected) exposure to tuberculosis*.

The frequency of such skin testing should be according to the degree of risk of acquiring tuberculosis infection, as detailed in the following paragraphs. Routine tuberculin skin testing of children with no risk factors and residing in low-prevalence communities is not indicated.

Children for whom immediate skin testing is indicated:

- Children with contacts to persons with confirmed or suspected infectious tuberculosis, including contact to family members or associates in jail or prison in the last five years
- Children with radiographic or clinical findings suggesting tuberculosis
- Children immigrating from endemic areas, such as Asia, Africa, the Middle East, and Latin America
- Children with travel histories to endemic countries or significant contact with indigenous persons from such countries

Children who should be tested annually for tuberculosis:

- Children infected with human immunodeficiency virus (HIV)
- Incarcerated adolescents

Children who should be tested every two to three years:

- Children exposed to the following individuals who are HIV-infected: homeless residents of nursing homes, institutionalized adolescents or adults, users of illicit drugs, incarcerated adolescents or adults, and migrant farm workers

Children who have no risk factors but who reside in high-prevalence regions and children whose histories for risk factors are incomplete or unreliable should be considered for tuberculin (Mantoux) skin testing at 4 to 6 years old and 11 to 16 years old. The decision to test should be based on the local epidemiology of tuberculosis in conjunction with advice from regional tuberculosis control officials.

Family investigation is indicated whenever a tuberculin skin test result of a parent converts from negative to positive (indicating recent infection). Children of healthcare workers are not at increased risk of acquiring tuberculosis infection unless the workers’ tuberculin skin test results convert to positive or the workers have diagnoses of tuberculosis disease.

The skin test interpretation guidelines for indurations of 5, 10, and 15mm in diameter remain appropriate for decisions about contact investigations, tuberculosis control measures, and preventive therapy.
Sickle Cell Anemia Testing

Early detection of sickle cell is important, because oral prophylactic penicillin should be started by 2 months old to prevent life-threatening infections. Children with sickle cell should be immunized as recommended by the AAP immunization schedule. They should also receive pneumococcal vaccine at 2 years old.

For more information about sickle cell anemia, contact the Indiana Family Helpline at 1-800-433-0746.

STD and STI Screening

All sexually active adolescents must be considered at high risk for most sexually transmitted diseases (STDs) and sexually transmitted infections (STIs).

HIV Testing

Common HIV tests use protein products of the virus to detect antibodies produced by the infected host. The two antibody tests used most commonly are Enzyme-Linked ImmunoSorbent Assay (ELISA) and Western Blot.

These tests are not 100% sensitive and require the production of antibody by the host and the absence of cross-reaching antibodies. Newer methodologies have been developed to divide HIV-1 tests into several groups:

- Virus culture techniques
  - Peripheral blood mononuclear cells (PBMC) co-culture for HIV-1 isolation
  - Quantitative cell culture
  - Quantitative plasma culture
- Antibody detection tests
- Antigen detection tests
- Viral genome amplification tests
- Immune function tests

False positive ELISA reactions generally result from cross-reaching antibodies, such as those against class II human leukocyte antigens that are most often observed in multiparous women or in a person who has received multiple units of transfused blood. A common misconception is that a false positive ELISA will always be corrected by the confirmatory Western Blot test.

The most important parameter when interpreting HIV tests is the positive predictive value. The probability of a positive test result occurring in a truly infected individual is critically dependent on the prevalence of HIV infection of the population tested. In testing HIV drug users from a major U.S. city in which the seroprevalence is 50%, the positive predictive value would approach 100%. Conversely, in screening female schoolteachers from a rural area where the seroprevalence is 0.01%, 50% of the women testing positive would have a false positive result. The likelihood of two false negative tests (ELISA and Western Blot) is very low, even in areas where seroprevalence is low.

The most sensitive and specific tests for chlamydia and gonorrhea are those involving deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) amplification (ligase chain reaction [LCR] and polymerase chain reaction [PCR]). Informed consent must be obtained from the individual. These tests are not an acceptable or reliable way to determine if an adolescent is sexually active. Samples must be obtained from the endocervix or endourethra. Culture of urine for these organisms is unsatisfactory.
Antigen detection (ELISA or direct fluorescent antibody) for chlamydia or gonorrhea is less sensitive than other methods.

Asymptomatic pyuria (WBC) can be detected using dipsticks for leukocyte esterase. Among sexually active adolescents, the likelihood of infection with an STD or STI is increased when leukocyte esterase is detected. Subsequent evaluation to identify the etiology of the pyuria is indicated. Chlamydia urethritis must be considered when leukocyte esterase is identified in the urine of adolescent males.
Section 7: Dental Observation and Screening

Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch providers are required to perform a dental observation to determine the need for diagnosis and treatment. Physicians are recommended to refer children for dental services, based on risk assessment, as early as 6 months of age, 6 months after the first tooth erupts, and no later than 12 months of age.

Tables 12 and 13 show recommendations for timing of screenings.

**Table 12 – IHCP EPSDT Dental Periodicity Schedule, Adapted from the American Academy of Pediatric Dentistry (AAPD)**

<table>
<thead>
<tr>
<th>Procedure</th>
<th>6–12 months</th>
<th>12–24 months</th>
<th>2–6 years</th>
<th>6–12 years</th>
<th>&gt;12 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical oral examination</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Assess oral growth and development</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Caries-risk assessment</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Anticipatory guidance/counseling</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Injury prevention counseling</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Counseling for nonnutritive habits</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Counseling for speech/language development</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Substance abuse counseling</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Counseling for intraoral/perioral piercing</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Assessment for pit and fissure sealants</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Transition to adult dental care</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Radiographic assessment</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Prophylaxis and topical fluoride</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Assessment and treatment of developing malocclusion</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
<tr>
<td>Assessment and/or removal of third molars</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td>■</td>
</tr>
</tbody>
</table>

1. First examination at the eruption of the first tooth and no later than 12 months. Repeat every six months or as indicated by child’s risk status/susceptibility to disease.

2. Includes assessment of pathology and injuries.

3. By clinical examination.

4. Must be repeated regularly and frequently to maximize effectiveness.

5. Timing, selection, and frequency determined by child’s history, clinical findings, and susceptibility to oral disease.

6. Appropriate discussion and counseling should be an integral part of each visit for care.

7. Initially play objects, pacifiers, car seats; then, when learning to walk, sports and routine playing, including the importance of mouth guards.

8. At first, discuss the need for additional sucking: digits versus pacifiers; then, the need to wean from the habit before malocclusion or skeletal dysplasia occurs. For school-aged children and adolescent patients, counsel regarding any existing habits such as fingernail biting, clenching, or bruxism.

9. For caries-susceptible primary molars, permanent molars, premolars, and anterior teeth with deep pits and fissures; placed as soon as possible after eruption.
### Table 13 – Periodicity Schedule for EPSDT/HealthWatch Dental Observation and Screening

<table>
<thead>
<tr>
<th>Age of Child</th>
<th>Subjective (S) or Required (R)</th>
<th>Services Required or Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Younger than 12 months</td>
<td>S</td>
<td>Direct referral to a dentist for medically appropriate services, if warranted by injury, disease, congenital abnormality, or other cause</td>
</tr>
<tr>
<td>12 to 24 months</td>
<td>S</td>
<td>Direct referral to a dentist, if medically appropriate</td>
</tr>
<tr>
<td>24 months</td>
<td>R</td>
<td>Direct referral to a dentist for examination, preventive dental care, and anticipatory guidance</td>
</tr>
<tr>
<td>24 months through 20 years</td>
<td>R</td>
<td>Regular dental assessments at intervals defined by the dentist (approximately every six months) for the individual patient Assessments should include examination, preventive dental care, and anticipatory guidance</td>
</tr>
</tbody>
</table>

An oral screening should be included as part of each EPSDT visit. **This service is not separately billable.** This EPSDT screening component includes an assessment of the following:

- Palate, checks, tongue, and floor of mouth
- Dental ridges (including erupting teeth)
- Gums for evidence of infection, bleeding, and inflammation
- Malformation or decay of erupting teeth
- Need for daily fluoride intake
- Need for dental referral regardless of age for a complete examination of all hard and soft tissues within the oral cavity

Poor oral health has been related to decreased school performance, poor social relationships, and less success later in life.

### Required Dental Referral

Note: In addition to the oral examination, a referral to a dentist must be a part of every screening, beginning at 24 months of age and continuing through 20 years old.

Dental referrals can be made as early as 6 months old, if indicated. Children should visit a dentist every six months after the first referral to receive preventive dental care. The first examination by a dentist can reveal decay, unerupted or missing teeth, and the need for prophylaxis or treatment.

See [Dental Health Education for Parents](#) for more information about dental health education and anticipatory guidance.
Section 8: Health Education and Anticipatory Guidance

Health education, including anticipatory guidance, is a required component of Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) services. At the outset, the physical or dental screening provides the initial context for providing health education. Health education and counseling to parents or guardians and to children is required and is designed to assist in understanding what to expect in terms of the child’s development. Health education provides information about the benefits of healthy lifestyles and practices as well as accident and disease prevention.

*Bright Futures Guidelines for Health Supervision of Infants, Children and Adolescents* outlines sample questions for each visit under the EPSDT schedule, to address the expert panel’s anticipatory guidance priorities for early childhood, middle childhood, and adolescence. The intention of this resource is to invite discussion, gather information, address needs and concerns, and build a partnership with each family member.

At each screening visit, provide age-appropriate education and guidance concerning such topics as the following:

- Auto safety – Car seats, seat belts, air bags, positioning young or lightweight children in the backseat
- Recreational safety – Helmets and protective padding, playground equipment
- Home hazards – Poisons, accidental drowning, weapons, matches and lighters, staying at home alone, use of detectors for smoke, radon gas, and carbon monoxide
- Exposure to sun and secondhand smoke
- Alcohol and tobacco use
- Substance abuse
- Adequate sleep
- Exercise and nutrition, including eating habits and disorders
- Sexual activity
- Peer pressure
- Immunization and blood testing as required

**Dental Health Education for Parents**

Among the many dental conditions affecting children, dental caries (tooth decay) is the preeminent concern in the context of Medicaid services because of its substantial prevalence in the low-income population. Tooth decay continues to be the single most common chronic disease among U.S. children, despite the fact that it is highly preventable through early and sustained home care and regular professional preventive services.

Parents should be counseled on the importance of taking care of their babies’ teeth. Teeth are susceptible to decay as soon as they appear in the mouth. Teeth can be brushed as soon as they appear.
Printed information about baby bottle tooth decay is available from the Indiana State Department of Health (ISDH):

**Oral Health**
Indiana State Department of Health
2 North Meridian Street, Section 7G
Indianapolis, IN 46204
Email: oralhealth@isdh.state.in.us
Website: in.gov/isdh/18717.htm
Indiana Family Helpline: 1-800-433-0746

Dental caries is generally considered to be reversible or capable of being arrested in the earliest stages through a variety of proven interventions. Beyond the early stages, the decay process generally tends to advance and become more difficult and costly to repair the longer it remains untreated. Therefore, treatment initiated early in the course of dental caries development will almost always be easier for both child and dentist, less expensive, and more successful than treatment begun at a later time.

Dental care is one of the most commonly unmet treatment needs in children. Lower-income children have more untreated dental disease than more affluent children who obtain care on a regular periodic basis. Reasons for this disparity include the fact that low-income children are more likely to experience dental disease and frequently only access care on an episodic or urgent basis when decayed teeth cause pain or swelling.

It is generally recommended by the American Academy of Pediatric Dentistry (AAPD) that children receive dental care at six-month intervals or as indicated by the patient’s needs or risk for disease. See the Dental Observation and Screening section of this document for detailed recommendations regarding the periodicity of professional dental services for children.

**Education Regarding Lead Poisoning for Pregnant Women and Children 6 Years Old or Younger**

Lead poisoning is preventable. The key to successful prevention is to educate parents with young children about the potential sources of lead poisoning.

A pamphlet entitled *Lead – Is Your Child at Risk?* is available for use in offices. To order pamphlets, call the Family Helpline at 1-800-433-0746.

**Referrals to Other Healthcare Programs**

**Children’s Special Health Care Services**

Children’s Special Health Care Services (CSHCS) is a medical coverage program that provides financial assistance for needed medical treatment to reduce complications and promote maximum quality of life for children, from birth to 21 years of age, with serious and chronic medical conditions.

Eligibility for CSHCS is based on both medical and financial criteria. Medical eligibility requires that a child be under 21 years of age and have a severe chronic medical condition that meets one of the following requirements:

- Has lasted (or is expected to last) at least two years
- Will produce disability or disfigurement or limits on function
- Requires a special diet or devices
- Would produce a chronic disabling physical condition if untreated
A family with an income (before taxes) at or below 250% of the federal poverty level may qualify.

Individuals can be enrolled in both the Indiana Health Coverage Programs (IHCP) and CSHCS if they qualify for both programs. The EPSDT services must first be billed to the IHCP network (fee-for-service or managed care) to which the child is assigned before submitting the claim to CSHCS. If the child is also enrolled in First Steps and First Steps covers the service, providers should bill First Steps first, and First Steps will coordinate billing the IHCP and CSHCS.

**Indiana’s First Steps Program**

Indiana’s First Steps early intervention system is a comprehensive, family-centered, community-based program that provides early intervention services to infants and young children with disabilities and those who are at risk for developmental delays. The First Steps program can provide a multidisciplinary evaluation and developmental assessment when children are referred. Early intervention services and/or supports are provided if the child is eligible; the services and supports are not income-based.

Families who are eligible to participate in the Indiana First Steps program include any child, from birth to 3 years old, who:

- Is experiencing developmental delays
- Has a diagnosed condition that has a high probability of resulting in a developmental delay
- Is at risk of having substantial developmental delay because of biological risk factors

All early intervention services must be agreed upon in advance by the child’s parents, included on an Individualized Family Service Plan (IFSP), and be provided by qualified personnel. An IFSP is the written plan detailing the early intervention services or supports the child will receive.

All infants and toddlers are entitled to evaluation to determine eligibility, ongoing assessment, and case management. The following services are specifically listed in the regulations. If appropriate for the child and family, they are included in the family’s IFSP:

- Audiology
- Case management/service coordination
- Family training, counseling, and home visits
- Health services necessary to enable the infant or toddler to benefit from the early intervention services
- Medical services only for diagnostic and evaluation purposes
- Nursing services
- Nutrition services
- Occupational therapy
- Physical therapy
- Psychological services
- Social work services
- Special instruction
- Speech-language pathology
- Transportation (direct and related costs of travel)
Although most First Steps agencies can provide all the early intervention services needed by children with developmental delays, IHCP members have the freedom of choice of providers for IHCP-covered services. Families can choose to receive IHCP-covered services from a provider not affiliated with the First Steps program.

In addition to the services children and their families can receive, it is important to get children with suspected or diagnosed developmental delays enrolled in the First Steps program for the following two special reasons:

- To enable eligible children and their families to receive early intervention services based on an IFSP
- To enable eligible children and their families to receive transitioning services when the child turns 3 years old and the Department of Education then becomes responsible for providing services for these children, if eligible, through an Individualized Education Plan (IEP)

Contact 1-800-441-STEP (7837) for more information about the First Steps program.

Services authorized by First Steps for children who are not enrolled in the IHCP and some CSHCS are billable only to First Steps. Non-First Steps services billed for IHCP members follow normal protocol for each delivery system.
Section 9: Documentation Resources

Documentation for the Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)/HealthWatch screenings should be incorporated into the documentation routinely kept for well-child check-ups. Because only a few activities differentiate EPSDT/HealthWatch screening components and well-child services, it is imperative that those differences be reflected in the member’s health record.

When screenings reveal the need for more frequent health exams or monitoring than recommended by the periodicity schedule, interperiodic screenings may be performed. The Indiana Health Coverage Programs (IHCP) covers interperiodic office visits and EPSDT screening exams up to the 30-office-visit maximum per individual, per year.

Review the Evaluation and Management Services and Claim Submission and Processing modules for information about billing non-EPSDT office visits and the office visit benefit limitation. Additional office visits, other than EPSDT screening exams, must be billed with appropriate evaluation and management (E/M) procedure codes for visits that are not full EPSDT/HealthWatch screenings and should not be billed using Z00.121 or Z00.129 as the primary diagnosis, so that they are reimbursed accordingly. If present and applicable, commercial insurance should be billed first.

The following sections present tools available for physicians’ use in simplifying documentation of EPSDT/HealthWatch screening components in medical records.

American Academy of Pediatrics

The Committee on Practice and Ambulatory Medicine publishes the Academy's preventive care guidelines, Recommendations for Preventive Pediatric Health Care. Also known as the periodicity schedule, the guidelines set forth recommendations for the periodicity of the well-child visits and the types of screens and health assessments that should be conducted at each visit.

The Family and Social Services Administration (FSSA) has identified the American Academy of Pediatrics (AAP) periodicity schedule to be “best practice” and supports the schedule as the appropriate guidelines for EPSDT services.

If you have any questions, contact the Council on Community Pediatrics toll-free at 1-800-433-9016 or see the American Academy of Pediatrics website at aap.org.

Bright Futures

Bright Futures is a national health promotion initiative dedicated to the principle that every child deserves to be healthy and that optimal health involves a trusting relationship between the health professional, the child, the family, and the community as partners in health practice.

The history of the patient is an important factor in making a proper assessment of the patient’s health. The EPSDT/HealthWatch screening physician has the responsibility of obtaining a family and medical history as part of the EPSDT screening examination.

Bright Futures Guidelines for Health Supervision of Infants, Children, and Adolescents has resources for documenting the components of EPSDT services for all ages.

Certainly, no health provider has the time to do every intervention discussed in the Bright Futures guidelines for each age visit. The FSSA has committed to put into practice the guidelines set forth by the AAP, as described in the Bright Futures Guidelines for Health Supervision of Infants, Children and Adolescents.
For complete information about Bright Futures, see the Bright Futures website at brightfutures.aap.org or contact Bright Futures at:

**Bright Futures at AAP**  
c/o American Academy of Pediatrics  
Bright Futures National Center  
141 Northwest Point Boulevard  
Elk Grove, IL 60007  
Email: brightfutures@aap.org

The following information can be obtained at the Bright Futures website:

- Previsit Questionnaires
- Supplemental Questionnaires
- Visit Documentation Forms
- Medical Screening Questionnaires
- Parent/Patient Education Handouts
- Guidelines for Health Supervision

### Centers for Disease Control and Prevention, National Center for Health Statistics

A detailed medical growth chart designed for each age group is available from the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). The CDC can be contacted in one of the following ways:

**Centers for Disease Control and Prevention**  
1600 Clifton Road  
Atlanta, GA 30329-4027  
Toll-Free Telephone: 1-800-232-4636  
Website: [Contact CDC-INFO](https://www.cdc.gov/growthcharts) at cdc.gov/growthcharts

Providers are also encouraged to periodically check the CDC NCHS website for announcements and updates about distribution and training materials.

### Indiana State Department of Health

The Indiana State Department of Health (ISDH) uses the [Recommendations for Preventive Pediatric Health Care](https://www.aap.org/en-us/advocacy-and-policy/healthy-children-communities/pediatric-health-care-recommendations) for the care of children who are receiving competent parenting, have no manifestations of any major health problems, and are growing and developing in satisfactory fashion. These guidelines represent a consensus by the Committee of Practice and Ambulatory Medicine in consultations with the national committees and sections of the AAP.

For more information, contact:

**Maternal and Child Health Services**  
Indiana State Department of Health  
2 North Meridian Street, Section 7C  
Indianapolis, IN 46204  
Toll-Free Telephone: 1-800-433-0746  
Fax: (317) 233-1299